Lilly licenses Mitsubishi anti-HBV compound

Mitsubishi-Tokyo Pharmaceuticals (Tokyo, Japan) granted LLY exclusive rights outside Japan to develop and market its MCC-478 antiviral nucleotide analog to treat hepatitis B virus (HBV) infection. The...